Migraine Headache
Conditions
Keywords
migraine, prophylactic treatment, cupping, serkangabin
Brief summary
Migraine is the most common recurrent headache. Current therapy of migraine headache consists of multiple drug groups for control of attack and prophylaxis against recurrent attacks. Emerging alternative medicine worldwide led investigators to evaluate the efficacy of cupping therapy plus SERKANGABIN syrup in treatment of migraine headache. Severity, duration and frequency of attacks of migraine headache evaluated in two groups during six months from presentation.
Detailed description
In a randomized controlled trial investigators randomly assigned 76 patients with migraine to cupping therapy plus SERKANGABIN or to receive conventional medical treatment. The use of CAM in migraine is a growing phenomenon. Migraine patients seek and explore both conventional and CAM approaches. Wet cupping is an ancient medical technique still used in several contemporary societies. It is being used in management of hypertension, diabetes mellitus, and headaches, renal and biliary stones and for maintaining health. Little experimental study has been devoted to test its efficacy to treat migraine headache. Investigators planned this study for evaluation of therapeutic efficacy of wet cupping and an Iranian traditional medicine preparation, SERKANGABIN in treatment of migraine headache compared with current medicine protocols. SERKANGABIN is a preparation of honey, vinegar and distilled mint water that in traditional Iranian medicine is believed to have therapeutic effects in many diseases (diabetes mellitus, hypertension, hyperlipidemia, osteoarthritis, chronic obstructive airway disease, interstitial lung disease, hepatitis, fatty liver, ischemic heart disease, migraine, cerebrovascular diseases)
Interventions
PROCEDUREcupping and serkangabin syrup
wet cupping serkangabin syrup
DRUGconventional migraine drug treatment
nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
Sponsors
Birjand University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* migraine headache with or without aura
Exclusion criteria
* uncontrolled hypertension * ischemic heart disease * cardiac arrhythmia or symptomatic Wolff-Parkinson-White syndrome * previous stroke or transient ischemic attack * severe liver or renal impairment * any other severe or disabling medical condition * history of alcohol or analgesic or psychotropic drug abuse * contraindication to or known hypersensitivity to study drugs * current use or use in the previous 2 weeks of MAO-inhibitors * a pain disorder other than migraine as the primary presenting problem * current psychological treatment, psychiatric disorder needing immediate or priority treatment * current or planned breast feeding or pregnancy or unwillingness to use an established contraceptive method * non compliance of patients * not presenting at times determined for treatment and evaluation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| frequency of migraine attacks per week | 2 weeks after first presentation | endpoints evaluated in both study groups 2 weeks after first presentation and receiving treatment protocols |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| severity of migraine attacks | 2 weeks after first presentation | severity of migraine attacks evaluated 2 weeks after first presentation in two study groups |
| duration of migraine attacks | 2 weeks after first presentation | duration of migraine attacks evaluated 2 weeks after first presentationin two study groups |
| frequency of migraine attacks | 1 month after first presentation | frequency of migraine attacks evaluated 1 month after first presentation in two study groups |
Countries
Iran
Outcome results
None listed